I am Deepankar, but I usually go by the shorter version: “Deep”. I did my PhD research at the University of Turku in Finland (public defense scheduled in February 2023). I was actively involved in several projects, predominantly in the field of Cancer Genetics, which were aimed at understanding molecular mechanisms of different human cancers and identifying opportunities for developing targeted therapeutics.
During the PhD, I developed a new high-throughput screen to discern activating mutations in kinases by constructing a cDNA library encompassing all possible point-mutations in the said kinase. So far, the screen has been used to study the EGFR family of RTKs (EGFR, HER2, HER3, and HER4) and identify activating mutations and assess their druggability with various TKIs. Using my screening workflow I am also investigating therapeutic resistance to ERBB-targeted inhibitors.
Here is my detailed CV in a PDF format.
PhD (Medical Biochemistry and Genetics), 2015 - 2022
Institute of Biomedicine, University of Turku, Finland
MSc (Bioinformatics), 2012 - 2014
Turku Centre for Biotechnology, University of Turku, Finland
B.Tech in Biotechnology, 2008 - 2012
Amity Institute of Biotechnology, Amity University, India
Conducting Functional Genetics research at the laboratory of Prof. Klaus Elenius. My responsibilities included:
ERBB4 is a member of the ERBB family of oncogenes (with EGFR, HER2 & HER3). ERBB4 is frequently mutated in different cancers, but the functional impact of its somatic mutations remains unknown. Here, in an unbiased functional genetics screen, we analyzed the function of over 8,000 ERBB4 variants that were generated by random mutagenesis. The data indicate the presence of rare activating ERBB4 mutations in cancer, with potential to be targeted with clinically approved pan-ERBB inhibitors.
I ❤️ Primes!
Swim & Snorkel
Shell, R, Python
‘Always happy to discuss these’
The Office, Dark, Chuck
Equities, ETFs, #Essentialism
Pihole, DNS resolvers, FOSS